Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Multicentric castleman disease (MCD) is an aggressive form of Castleman disease that mostly results from human herpesvirus 8 (HHV8) infection. It manifests by fever, diffuse lymphadenopathy, hepatosplenomegaly, Involvement of the respiratory system and increased C-reactive protein.
Biomarker and diagnostic research for multicentric Castleman disease has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
8 clinical trials registered, 4 recruiting. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 4 PHASE2. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT00006518](https://clinicaltrials.gov/study/NCT00006518) |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 9:41 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer |
— |
National Cancer Institute (NCI) |
RECRUITING |
[NCT00092222](https://clinicaltrials.gov/study/NCT00092222) | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | PHASE2 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
[NCT03933904](https://clinicaltrials.gov/study/NCT03933904) | Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease | PHASE2 | University of Pennsylvania | ACTIVE_NOT_RECRUITING |
[NCT05663502](https://clinicaltrials.gov/study/NCT05663502) | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | — | AIDS Malignancy Consortium | RECRUITING |
[NCT06052618](https://clinicaltrials.gov/study/NCT06052618) | Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
218 publications have been identified in PubMed for multicentric Castleman disease. Research spans Case Report / Case Series (49%), Review / Meta-Analysis (12%), and Basic Science / Preclinical (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 106 | 49% |
Research summaries | 27 | 12% |
Laboratory research | 26 | 12% |
Disease patterns and progression | 19 | 9% |
Testing and diagnosis research | 16 | 7% |
Clinical study results | 15 | 7% |
Other research | 6 | 3% |
New treatment approaches | 3 | 1% |
Mularoni A (2026). [PMID: 41615270](https://pubmed.ncbi.nlm.nih.gov/41615270/). *Transplant infectious disease : an official journal of the Transplantation Society*. [Review / Meta-Analysis]
Zhang S (2026). [PMID: 41942330](https://pubmed.ncbi.nlm.nih.gov/41942330/). *Zhonghua nei ke za zhi*. [Case Report / Case Series]
Pelliccia S (2026). [PMID: 41889412](https://pubmed.ncbi.nlm.nih.gov/41889412/). *Frontiers in oncology*. [Case Report / Case Series]
Fukui S (2026). [PMID: 41922262](https://pubmed.ncbi.nlm.nih.gov/41922262/). *Drug discoveries & therapeutics*. [Clinical Trial Publication]
Laczko D (2026). [PMID: 41802815](https://pubmed.ncbi.nlm.nih.gov/41802815/). *American journal of clinical pathology*. [Diagnostic / Biomarker]
Alapat DV (2026). [PMID: 41774910](https://pubmed.ncbi.nlm.nih.gov/41774910/). *American journal of clinical pathology*. [Diagnostic / Biomarker]
Ueda Y (2026). [PMID: 41100060](https://pubmed.ncbi.nlm.nih.gov/41100060/). *Rheumatology (Oxford, England)*. [Diagnostic / Biomarker]
Quon S (2026). [PMID: 41840344](https://pubmed.ncbi.nlm.nih.gov/41840344/). *American journal of hematology*. [Case Report / Case Series]
Dieudonné Y (2026). [PMID: 41959728](https://pubmed.ncbi.nlm.nih.gov/41959728/). *HemaSphere*. [Clinical Trial Publication]
Gupta R (2026). [PMID: 41694934](https://pubmed.ncbi.nlm.nih.gov/41694934/). *Cureus*. [Case Report / Case Series]
AI-curated news mentioning multicentric Castleman disease
Updated Sep 16, 2026
A recent study published in PubMed examines the clinical characteristics and surgical outcomes of retroperitoneal unicentric Castleman disease. This single-center retrospective analysis provides valuable insights into patient management and treatment efficacy.
Recent research highlights new management strategies for Castleman disease, aiming to improve patient outcomes. These findings could influence future treatment protocols and clinical practices.
A Canadian center has applied modern classification methods to improve the understanding of Castleman disease. This research aims to enhance diagnostic accuracy and treatment approaches for this rare condition.